1. Home
  2. BLW vs ASMB Comparison

BLW vs ASMB Comparison

Compare BLW & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Limited Duration Income Trust

BLW

Blackrock Limited Duration Income Trust

HOLD

Current Price

$13.81

Market Cap

533.4M

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$34.75

Market Cap

553.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLW
ASMB
Founded
2003
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
533.4M
553.6M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
BLW
ASMB
Price
$13.81
$34.75
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$43.40
AVG Volume (30 Days)
85.9K
115.0K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
8.83%
N/A
EPS Growth
N/A
N/A
EPS
1.81
N/A
Revenue
N/A
$37,191,000.00
Revenue This Year
N/A
$42.01
Revenue Next Year
N/A
N/A
P/E Ratio
$7.73
N/A
Revenue Growth
N/A
31.30
52 Week Low
$12.35
$7.75
52 Week High
$14.26
$39.71

Technical Indicators

Market Signals
Indicator
BLW
ASMB
Relative Strength Index (RSI) 53.23 52.92
Support Level $13.69 $32.25
Resistance Level $13.77 $36.92
Average True Range (ATR) 0.08 1.68
MACD 0.01 -0.47
Stochastic Oscillator 56.27 41.71

Price Performance

Historical Comparison
BLW
ASMB

About BLW Blackrock Limited Duration Income Trust

Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: